1. Experimental Guillain-Barre syndrome induced by immunization with gangliosides: Keyhole limpet hemocyanin is required for disease triggering.
- Author
-
Funes SC, Chiari ME, Comín R, Irazoqui FJ, and Nores GA
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Disease Models, Animal, Hemocyanins pharmacology, Humans, Rabbits, Adjuvants, Immunologic administration & dosage, Antibody Formation drug effects, Guillain-Barre Syndrome chemically induced, Guillain-Barre Syndrome immunology, Guillain-Barre Syndrome pathology, Hemocyanins adverse effects, Immunization adverse effects, Models, Immunological
- Abstract
An experimental model of Guillain-Barré Syndrome has been established in recent years. Rabbits develop disease upon immunization with a single dose of an emulsion containing bovine brain gangliosides, KLH and complete Freund's adjuvant. Within a period of four to ten weeks after immunization, they began to produce anti-ganglioside IgG-antibodies first, and to show clinical signs of neuropathy afterwards. In addition to gangliosides, KLH is a requirement for antibody production and disease triggering. Although KLH is commonly used as an immunological carrier protein, an anti-KLH-specific immune response was necessary for induction of both events. KLH is a glycoprotein carrying most of the immunogenicity in its glycan moiety. Between 20% to 80% of anti-ganglioside IgG-antibodies present in sick rabbit sera cross-reacted with KLH, indicating that both immune responses are related. The terminal Gal-ß(1,3)-GalNAc glycan (present in gangliosides and KLH) is proposed as "key" antigenic determinant involved in inducing the anti-ganglioside immune response. These results are discussed in the context of the "binding site drift" hypothesis., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF